The investment objective of the scheme is to provide returns before expenses that closelycorrespond to the total return of the underlying index subject to tracking errors.
Expert-managed portfolios tailored to your financial goals and risk appetite.
| ETFs | 1M | 3M | 6M | 9M | 1Y | 2Y | 3Y | 4Y | 5Y | 10Y | ALL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund returns | -6.38% | -4.44% | 7.56% | 9.19% | 5% | 3.29% | 17.87% | 17.71% | 12.38% | N/A | 12.86% |
| Category returns | -2.99% | -4.52% | -3.02% | -5.03% | -4.77% | -2.03% | 9% | 10.98% | 7.45% | 11.5% | N/A |
| Absolute returns | -6.38% | -4.44% | 7.56% | 9.19% | 5% | 6.69% | 63.85% | 92.07% | 79.29% | N/A | 92.74% |
| Rank within category | 247/268 | 90/252 | 8/241 | 11/228 | 16/207 | 27/162 | 9/134 | 13/112 | 9/81 | N/A | N/A |
| ETFs | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Yearly returns | N/A | -10.19% | 33.76% | 41.13% | -1.62% | 6.65% |
| Q1 returns | N/A | -5.33% | -4.52% | 13.54% | -8.37% | -2.85% |
| Q2 returns | N/A | -11.3% | 17.24% | 4.27% | 5.8% | 13.72% |
| Q3 returns | 2.39% | 9.79% | 9.19% | 17.66% | -1.97% | 0.14% |
| Q4 returns | -0.1% | -2.58% | 9.44% | 1.32% | 3.51% | -3.6% |
| Alpha | -0.0068633 |
| Beta | 0.9997 |
| Sharpe Ratio | 0.272509 |
| Sortino Ratio | 0.5875 |
| R-Squared | 0.9971 |
| Tracking Error | 0.0586 |
| Downside Risk | 17.2049 |
| Std. Deviation (Annualised) | 14.1756 |
| ETFs | 1M | 3M | 6M | 9M | 1Y | 3Y | 5Y | 10Y | ALL | Fund Size (Cr) | Exp. Ratio | Sharpe | Risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Motilal Oswal BSE Healthcare ETF | -7.16% | -4.01% | 10.11% | 12.75% | 6.7% | 19.48% | N/A | N/A | 19.41% | 44.40 | 0.36 | 0.30 | Very High |
| Nippon India Nifty Pharma ETF | -4.12% | -0.09% | 14.11% | 16.17% | 15.52% | 19.28% | 12.79% | N/A | 12.07% | 1,736.44 | 0.23 | 0.30 | Very High |
| Motilal Oswal BSE Enhanced Value ETF | -3.37% | -6.03% | -9.38% | -9.5% | -0.01% | 18.7% | N/A | N/A | 26.28% | 146.61 | 0.43 | 0.20 | Very High |
| DSP Nifty PSU Bank ETF | -0.29% | -1.08% | -5.84% | -7.11% | 9.24% | 18.66% | N/A | N/A | 20.49% | 1,434.17 | 0.16 | 0.15 | Very High |
| ICICI Prudential Nifty PSU Bank ETF | -0.32% | -1.15% | -6.01% | -7.33% | 8.91% | 18.53% | N/A | N/A | 26.2% | 118.61 | 0.41 | 0.15 | Very High |
| Nippon India ETF Nifty PSU Bank BeES | -0.32% | -1.17% | -6.04% | -7.39% | 8.81% | 18.35% | 25.56% | 10.01% | 6.93% | 3,932.00 | 0.51 | 0.14 | Very High |
| Kotak Nifty PSU Bank ETF | -0.32% | -1.17% | -6.06% | -7.4% | 8.79% | 18.33% | 25.56% | 9.94% | 6.36% | 2,490.74 | 0.51 | 0.14 | Very High |
| Aditya Birla Sun Life Nifty Healthcare ETF | -6.38% | -4.45% | 7.53% | 9.15% | 4.95% | 18.01% | 0% | N/A | 12.85% | 74.67 | 0.20 | 0.27 | Very High |
| ICICI Prudential Nifty Healthcare ETF Current | -6.38% | -4.44% | 7.56% | 9.19% | 5% | 17.87% | 12.38% | N/A | 12.86% | 231.43 | 0.16 | 0.27 | Very High |
| CPSE Exchange Traded Scheme | -4.68% | -8.11% | -17.4% | -5.64% | -6.14% | 17.73% | 22.49% | 13.23% | 13.75% | 18,645.20 | 0.08 | 0.19 | Very High |
| Name | Sector | Instrument | Assets % |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 17.00% |
| Divi's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 10.44% |
| Apollo Hospitals Enterprise Ltd. | Healthcare Services | Domestic Equities | 7.43% |
| Laurus Labs Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 6.82% |
| Cipla Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 6.69% |
| Dr. Reddy's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 6.65% |
| Torrent Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 6.24% |
| Max Healthcare Institute Ltd. | Healthcare Services | Domestic Equities | 6.12% |
| Lupin Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.36% |
| Aurobindo Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.08% |
| Fortis Healthcare Ltd. | Healthcare Services | Domestic Equities | 3.55% |
| Glenmark Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.11% |
| Alkem Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.75% |
| Zydus Lifesciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.54% |
| Mankind Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.51% |
| Ipca Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.37% |
| Biocon Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.28% |
| Gland Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.04% |
| Krishna Institute of Medical Sciences Ltd | Healthcare Services | Domestic Equities | 1.76% |
| Abbott India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.25% |
| TREPS | Cash & Cash Equivalents and Net Assets | 0.04% | |
| Net Current Assets | Cash & Cash Equivalents and Net Assets | -0.01% | |
| Total | 100.00% | ||
Mr. Nishit Patel joined ICICI Prudential Asset Management Company Limited in November 2018.
Ms. Ashwini was appointed as the Deputy Manager - Dealer Support in the Investment Department of ICICI Prudential Asset Management Company Ltd. w.e.f. August 1, 2024. During November 2024, she was appointed as fund manager for certain passive schemes.
Mr. Venus Ahuja was appointed as dealer in the Investments Department of ICICI Prudential Asset AMC.
Get personalized portfolio management services designed to grow and protect your wealth.
ChatGPT
Claude
Perplexity
